A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis
Condition:   Atopic Dermatitis Intervention:   Drug: Ruxolitinib cream Sponsor:   Incyte Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2019 Category: Research Source Type: clinical trials

A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Subjects With Atopic Dermatitis (AD)
Condition:   Atopic Dermatitis Intervention:   Biological: Nemolizumab Sponsor:   Galderma R&D Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2019 Category: Research Source Type: clinical trials

A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis
Condition:   Atopic Dermatitis Intervention:   Drug: Ruxolitinib cream Sponsor:   Incyte Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2019 Category: Research Source Type: clinical trials

Single Dose and Multiple Dose Study to Assess Safety and Tolerability of LOU064
Condition:   Healthy Volunteers, Atopic Diathesis and Atopic Dermatitis Interventions:   Drug: LOU064;   Drug: Placebo Sponsor:   Novartis Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2019 Category: Research Source Type: clinical trials

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: PF-04965842 200 mg;   Drug: PF-04965842 100 mg;   Drug: Placebo Sponsor:   Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2019 Category: Research Source Type: clinical trials

Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: ARQ-151 cream 0.05%;   Drug: ARQ-151 cream 0.15%;   Drug: ARQ-151 cream Vehicle Sponsor:   Arcutis, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2019 Category: Research Source Type: clinical trials

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: PF-04965842 200 mg;   Drug: PF-04965842 100 mg;   Drug: Placebo Sponsor:   Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2019 Category: Research Source Type: clinical trials

Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: ARQ-151 cream 0.05%;   Drug: ARQ-151 cream 0.15%;   Drug: ARQ-151 cream Vehicle Sponsor:   Arcutis, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2019 Category: Research Source Type: clinical trials

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: PF-04965842 200 mg;   Drug: PF-04965842 100 mg;   Drug: Placebo Sponsor:   Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2019 Category: Research Source Type: clinical trials

Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: ARQ-151 cream 0.05%;   Drug: ARQ-151 cream 0.15%;   Drug: ARQ-151 cream Vehicle Sponsor:   Arcutis, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2019 Category: Research Source Type: clinical trials

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: PF-04965842 200 mg;   Drug: PF-04965842 100 mg;   Drug: Placebo Sponsor:   Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2019 Category: Research Source Type: clinical trials

Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: ARQ-151 cream 0.05%;   Drug: ARQ-151 cream 0.15%;   Drug: ARQ-151 cream Vehicle Sponsor:   Arcutis, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2019 Category: Research Source Type: clinical trials

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: PF-04965842 200 mg;   Drug: PF-04965842 100 mg;   Drug: Placebo Sponsor:   Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2019 Category: Research Source Type: clinical trials

Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: ARQ-151 cream 0.05%;   Drug: ARQ-151 cream 0.15%;   Drug: ARQ-151 cream Vehicle Sponsor:   Arcutis, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2019 Category: Research Source Type: clinical trials

Internet and Social Media Use in Dermatology Patients
Condition:   Dermatologic Diseases Intervention:   Other: patient questionnaire Sponsor:   University Hospital, Basel, Switzerland Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2019 Category: Research Source Type: clinical trials

Dermal Micrografts in Regenerative Surgery
Condition:   Regenerative Medicine Intervention:   Procedure: Integra® dermal substitute and RigeneraTM protocol Sponsor:   Istituti Clinici Scientifici Maugeri SpA Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: 0.3% OPA-15406;   Drug: 1% OPA-15406;   Drug: Placebos Sponsor:   Otsuka Pharmaceutical Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: dupilumab SAR231893;   Drug: placebo;   Drug: Emollient (moisturizer) Sponsors:   Sanofi;   Regeneron Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Dermal Micrografts in Regenerative Surgery
Condition:   Regenerative Medicine Intervention:   Procedure: Integra® dermal substitute and RigeneraTM protocol Sponsor:   Istituti Clinici Scientifici Maugeri SpA Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: dupilumab SAR231893;   Drug: placebo;   Drug: Emollient (moisturizer) Sponsors:   Sanofi;   Regeneron Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: 0.3% OPA-15406;   Drug: 1% OPA-15406;   Drug: Placebos Sponsor:   Otsuka Pharmaceutical Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Dermal Micrografts in Regenerative Surgery
Condition:   Regenerative Medicine Intervention:   Procedure: Integra® dermal substitute and RigeneraTM protocol Sponsor:   Istituti Clinici Scientifici Maugeri SpA Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: 0.3% OPA-15406;   Drug: 1% OPA-15406;   Drug: Placebos Sponsor:   Otsuka Pharmaceutical Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: dupilumab SAR231893;   Drug: placebo;   Drug: Emollient (moisturizer) Sponsors:   Sanofi;   Regeneron Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Dermal Micrografts in Regenerative Surgery
Condition:   Regenerative Medicine Intervention:   Procedure: Integra® dermal substitute and RigeneraTM protocol Sponsor:   Istituti Clinici Scientifici Maugeri SpA Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: 0.3% OPA-15406;   Drug: 1% OPA-15406;   Drug: Placebos Sponsor:   Otsuka Pharmaceutical Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: dupilumab SAR231893;   Drug: placebo;   Drug: Emollient (moisturizer) Sponsors:   Sanofi;   Regeneron Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Dermal Micrografts in Regenerative Surgery
Condition:   Regenerative Medicine Intervention:   Procedure: Integra® dermal substitute and RigeneraTM protocol Sponsor:   Istituti Clinici Scientifici Maugeri SpA Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: 0.3% OPA-15406;   Drug: 1% OPA-15406;   Drug: Placebos Sponsor:   Otsuka Pharmaceutical Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: dupilumab SAR231893;   Drug: placebo;   Drug: Emollient (moisturizer) Sponsors:   Sanofi;   Regeneron Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Dermal Micrografts in Regenerative Surgery
Condition:   Regenerative Medicine Intervention:   Procedure: Integra® dermal substitute and RigeneraTM protocol Sponsor:   Istituti Clinici Scientifici Maugeri SpA Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: dupilumab SAR231893;   Drug: placebo;   Drug: Emollient (moisturizer) Sponsors:   Sanofi;   Regeneron Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: 0.3% OPA-15406;   Drug: 1% OPA-15406;   Drug: Placebos Sponsor:   Otsuka Pharmaceutical Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Dermal Micrografts in Regenerative Surgery
Condition:   Regenerative Medicine Intervention:   Procedure: Integra® dermal substitute and RigeneraTM protocol Sponsor:   Istituti Clinici Scientifici Maugeri SpA Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: 0.3% OPA-15406;   Drug: 1% OPA-15406;   Drug: Placebos Sponsor:   Otsuka Pharmaceutical Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: dupilumab SAR231893;   Drug: placebo;   Drug: Emollient (moisturizer) Sponsors:   Sanofi;   Regeneron Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Dermal Micrografts in Regenerative Surgery
Condition:   Regenerative Medicine Intervention:   Procedure: Integra® dermal substitute and RigeneraTM protocol Sponsor:   Istituti Clinici Scientifici Maugeri SpA Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: 0.3% OPA-15406;   Drug: 1% OPA-15406;   Drug: Placebos Sponsor:   Otsuka Pharmaceutical Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials

Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis
Condition:   Atopic Dermatitis Interventions:   Drug: dupilumab SAR231893;   Drug: placebo;   Drug: Emollient (moisturizer) Sponsors:   Sanofi;   Regeneron Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2019 Category: Research Source Type: clinical trials